VWM
SYRE icon

Venturi Wealth Management’s Spyre Therapeutics SYRE Stock Holding History

Venturi Wealth Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-231
Closed -$5.38K – 1676
2024
Q4 		$5.38K Buy
+231
New +$6.77K ﹤0.01% 1631

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Venturi Wealth Management's SYRE Position: Q1 2025 in Review

Venturi Wealth Management sold out of Spyre Therapeutics (SYRE) in Q1 2025, closing a stake of 231 shares — an estimated $5.38K sold.

Venturi Wealth Management first reported a position in SYRE in Q4 2024 and held it in 1 quarter. The position peaked at $5.38K in Q4 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q1 2025.

  • Venturi Wealth Management reported no remaining Spyre Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Venturi Wealth Management sold 231 Spyre Therapeutics shares in Q1 2025, an estimated $5.38K.
  • Venturi Wealth Management first reported a position in Spyre Therapeutics in Q4 2024 and held it in 1 quarter.
  • Venturi Wealth Management's Spyre Therapeutics position peaked at $5.38K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2025.

Based on Venturi Wealth Management's 13F filing for Q1 2025, filed 6 May 2025.